logo
"Don't put it off" Colorado father urges screenings after routine colonoscopy finds cancer

"Don't put it off" Colorado father urges screenings after routine colonoscopy finds cancer

CBS News25-03-2025
March is Colorectal Cancer Awareness Month, and Colorado doctors are warning the deadly disease is on the rise among young people. Diagnoses in people under 50 have risen by more than 50% since 1994.
When Castle Pines father of two Jeff Lind turned 45, his doctor told him it was time for his first colonoscopy.
"I did not want to do it because I've heard that it's, it's quite invasive," Lind said.
After putting off the screening procedure twice, Lind ultimately scheduled it for January of this year.
"It's the right thing to do for my health. I mean, if I'm by myself and don't have anybody who relies on me, then maybe that's a different story. But I have a family. I want to see them and see my kids grow," Lind said.
Despite the fact that Lind had no noticeable symptoms, doctors at AdventHealth found cancer in his colon.
"They found 10 polyps and a tumor, and it didn't look good," Lind said. "It's super scary. I didn't know what was going to happen. Am I going to make it through this? Am I going to see my kids grow up?"
A few weeks later, colorectal surgeon at AdventHealth in Castle Rock and Parker Dr. Ryan Smith operated on Lind, removing 10 inches of his colon.
"Jeff is a classic example of reason to get screened at age 45. He really didn't have any symptoms. He was going for a routine colonoscopy at the recommended age and found a mass in the distal part of his colon and first part of his rectum," said Smith.
Smith said colorectal cancer is on the rise in young people.
"We are seeing an increased incidence in colorectal cancer in patients under the age of 50. It's actually the leading cause of cancer-related death in men under 50, and it's the second leading cause of death in women under 50," Smith said.
It is recommended that adults should start getting a colonoscopy at age 45 and repeat every 10 years if no polyps are found. If you have symptoms or a family history, talk to your doctor about getting one sooner.
"If you do have a family history, it is an indication to get screened earlier. The recommendation is 10 years earlier to the onset of a family member, and then anytime you have symptoms, that is also an indication to get screened," said Smith. "Symptoms such as bleeding, weight loss changes in bowel habits; those are all indications to get evaluated. Oftentimes, things like that can get written off in the younger population. So it's really important to be your own advocate and when you know something is not right, to have it evaluated."
Lind said the procedure was not bad, but the preparation was terrible. Dr. Smith said the process is easy, safe and not worth putting off.
"I certainly think there can be a stigma. I don't think anybody enjoys the prep and everything that's required for a colonoscopy. And it's also easy to be one of those things that you keep putting off because of just life happening and inconvenience in everybody's busy schedule. But it should not be anything anybody is embarrassed about. It is something we recommend for everybody," Smith said.
Thanks to early detection, Lind is now cancer-free.
"It wouldn't have been identified if I hadn't gone when I turned 45, getting a colonoscopy. I could be in a much different place, you know. Say I didn't go for five years, who knows what, what would have happened?" Lind said.
He'll have to get a colonoscopy once a year but says it's a small price to pay for a future with his family.
"Don't put it off. Just go get it done," Lind said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery
$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery

Yahoo

time5 days ago

  • Yahoo

$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery

DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- What's fueling the shift from sterilization to scalability? The global single-use surgical instruments market, valued at US$5.60 billion in 2024, stood at US$5.92 billion in 2025 and is projected to advance at a resilient CAGR of 5.7% from 2025 to 2030, culminating in a forecasted valuation of US$7.80 billion by the end of the period. This growth is being driven by the rise of minimally invasive, short-stay, and outpatient surgeries—procedures that demand efficiency, sterility, and speed. Disposable tools are no longer just convenient—they are mission-critical assets for modern surgical care. Download PDF Brochure: Why are single-use surgical instruments becoming a new clinical benchmark? In high-risk surgeries such as general, ophthalmic, dental, and cardiovascular procedures, hospitals are under pressure to minimize infection, reduce turnaround time, and ensure tool readiness. Single-use instruments meet these demands with precise, sterile, ready-to-use tools that support faster recovery, reduce complications, and align with evolving patient care models like same-day discharge and ambulatory surgery. What challenges do single-use surgical instruments solve? They solve the pressing issues of cross-contamination, procedural inefficiency, and high sterilization costs. In underserved or rural healthcare facilities, limited access to reprocessing systems makes reusable tools a risk. Single-use surgical instruments eliminate these barriers, delivering hygienic, high-performance solutions that simplify workflows and improve patient safety. Where is adoption accelerating the fastest? Emerging markets such as India, Asia Pacific, Latin America, and sub-Saharan Africa are rapidly expanding healthcare infrastructure. With India conducting over 30 million surgeries annually, the demand for disposable, low-maintenance instruments are surging. These regions offer cost-effective pathways to scale sterile surgical care across both urban and rural settings. Request Sample Pages : Who are the key leaders—and how are they gaining ground? Market frontrunners include Ethicon, Medtronic, and BD, backed by global reach and deep R&D strength. Other major players like Smith+Nephew, STERIS, and B. Braun are expanding through acquisitions, strategic partnerships, and global training centers—including Smith+Nephew's surgical innovation center in Munich and STERIS's acquisition of BD's instrumentation business. What's the biggest challenge—and how do we overcome it? High cost and environmental sustainability are key hurdles. Smaller hospitals often rely on reusable tools due to budget limits. Simultaneously, increased medical waste is drawing scrutiny. Forward-thinking suppliers will win by delivering cost-efficient, eco-conscious single-use solutions backed by clear clinical and operational ROI. What should healthcare leaders be asking now?Not "Should we switch to disposables?"—but rather:• How can we cut infection risks without compromising efficiency?• Where can we reduce operational overhead from sterilization bottlenecks?• How do single-use instruments fit into our outpatient care strategy?• Which partners best align with our compliance, safety, and growth goals? Final Thought: In Sterility, There Is Strategy. In Simplicity, There Is global shift toward safe, efficient, and rapid-turnaround surgery is here. Single-use surgical instruments deliver the hygiene, performance, and reliability modern care demands. Facilities that embrace this model will lead on patient outcomes, cost control, and regulatory compliance. In the new era of surgery—precision, performance, and protection begin with single-use. For more information, Inquire Now! Related Reports: Surgical Sutures Market Wound Care Market Biosurgery Market Knee Replacement Surgery Market Surgical Suction Instruments Market Get access to the latest updates on Top Companies in Single-use Surgical Instruments and Single-use Surgical Instruments Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Listen to your gut
Listen to your gut

Washington Post

time01-07-2025

  • Washington Post

Listen to your gut

Karen Corbin, a nutrition and metabolism researcher at AdventHealth Translational Research Institute, walks us through her latest research on how our gut and metabolism respond to whole vs. ultraprocessed foods. Foods that optimize this gut-and-metabolism relationship allow your body to create and use up energy. To read Corbin's study, click here. For more on her work, go to her page on AdventHealth Translational Research Institute here. Now 'Try This' has a newsletter! Think of it as a supplemental guide and sign up here. Subscribe to The Washington Post or connect your subscription in Apple Podcasts.

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

Business Upturn

time29-06-2025

  • Business Upturn

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

By GlobeNewswire Published on June 29, 2025, 16:00 IST Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of 'Life Unlimited' – making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: With more than 150,000 procedures1 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact amongst those having surgery for rotator cuff tears; demonstrating lower re-tear rates than reported compared to conventional techniques.2-6 Backed by level one clinical evidence,2 the collagen-based implant supports the body's natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.7-12 CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant: Derived from a naturally occurring calcium carbonate known as aragonite, the CARTIHEAL Implant is a biphasic scaffold for cartilage repair and subchondral bone restoration.13-15 Shown to deliver clinically meaningful post-operative improvements in pain, function and quality of life,* the CARTIHEAL Implant is the only device approved for the treatment of knee cartilage and osteochondral defects in patients with or without mild to moderate osteoarthritis (KL 0-3).13,16 Q-FIX◊ KNOTLESS All-Suture Anchor: Building on the long-standing success and performance of the Q-FIX Family for best-in-class anchor fixation strength,**,17-21 the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for soft tissue security†,22 and offer surgeons a new option for soft tissue-to-bone fixation indications across multiple joint spaces. 'Our inaugural turn sponsoring select players during The Championships, Wimbledon in 2024 was a tremendous success supporting athletes from across the globe – including Jasmine Paolini all the way to the Ladies Final,' said Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. 'We were able to uniquely feature the Smith+Nephew brand along with our leading Sports Medicine technology portfolio – designed to help weekend warriors and world-class athletes get back to competing and doing what they love.' If you would like to learn more about Smith+Nephew's leading Sports Medicine technology portfolio – including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor – please visit here. – ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew [email protected] *Over a 2 and 4 year follow up **As compared to competitive devices in fixation/pull-out benchtop testing †As compared to the competitive device in cyclic benchtop testing References Smith+Nephew. Internal Data. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at One Year: A Randomized Controlled Trial. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2023:1-14. Bushnell BD, Connor PM, Harris HW, et al. Retear rates and clinical outcomes at 1 year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study. JSES international. 2021;5(2):228. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-2281. Camacho-Chacon JA, Cuenca-Espierrez J, Roda-Rojo V, et al. Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears. J Exp Orthop. 2022;9(1):53. Smith + Nephew overview of the outcomes associated with the standard of care for the surgical treatment of rotator cuff tears. Internal Report EO/SPM/REGENETEN/005/v1. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283 Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252 Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126 Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275. Smith+Nephew 2023. Internal Report. 10090792- Revision B. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B. Smith+Nephew 2024. Internal Report. 10144423 Rev B. Smith and Nephew 10144423 Rev B About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store